Начало › Рак на яйчниците › Alabama › Birmingham
Клинични проучвания за Рак на яйчниците в Birmingham, AL
23 проучвания за Рак на яйчниците търсят участници в обекти в и около Birmingham (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Набиране на участнициФаза 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Набиране на участнициФаза 2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Набиране на участнициФаза 2
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham
DESTINY-PANTUMOUR04
Набиране на участнициНаблюдателно проучване
- Research Site, Birmingham
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Набиране на участнициФаза 1/2
- University of Alabama_6th Ave, Birmingham
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Набиране на участнициФаза 3
- University of Alabama at Birmingham, Birmingham
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Набиране на участнициФаза 3
- University of Alabama - Birmingham ( Site 0058), Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Набиране на участнициНаблюдателно проучване
- University of Alabama at Birmingham, Birmingham
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Набиране на участнициФаза 2
- The University of Alabama at Birmingham, Birmingham
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Набиране на участнициФаза 1/2
- The University of Alabama, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Набиране на участнициФаза 1
- University of Alabama Birmingham, Birmingham
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Набиране на участнициФаза 3
- University of Alabama at Birmingham ( Site 0006), Birmingham
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Набиране на участнициФаза 1/2
- Children's Hospital of Alabama, Birmingham
Study of NTB-928 in R/R OC
Набиране на участнициФаза 1
- The University of Alabama, Birmingham
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Набиране на участници
- University of Alabama at Birmingham Cancer Center, Birmingham
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Набиране на участнициФаза 3
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- University of Alabama at Birmingham, Birmingham
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- University of Alabama at Birmingham, Birmingham
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Набиране на участнициФаза 2
- 004, Birmingham
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Набиране на участнициФаза 2
- University of Alabama at Birmingham Womens & Infants Center, Birmingham
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
Набиране на участнициФаза 2
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Набиране на участници
- University of Alabama at Birmingham, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Birmingham
Проучвания за Рак на яйчниците в други градове
- Houston, TX89 проучвания
- New York City, NY69 проучвания
- Boston, MA61 проучвания
- Los Angeles, CA50 проучвания
- Nashville, TN49 проучвания
- Arlington, VA46 проучвания
- Philadelphia, PA44 проучвания
- Columbus, OH39 проучвания
- St. Louis, MO38 проучвания
- Chicago, IL36 проучвания
- San Antonio, TX31 проучвания
- Cleveland, OH30 проучвания
Други проучвания в Birmingham
- Рак (всички видове)31 проучвания
- Рак на гърдата24 проучвания
- Затлъстяване23 проучвания
- Рак на белия дроб с недребноклетъчен тип22 проучвания
- Остра миелоидна левкемия21 проучвания
- Множествен миелом18 проучвания
- ХОББ17 проучвания
- Сърдечно-съдово заболяване17 проучвания
- Диабет тип 216 проучвания
- Ендометриален рак16 проучвания
- Наднормено тегло16 проучвания
- Муковисцидоза16 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.